dlat-1 Antibody
Description
Anti-DLAT Antibodies in Research
Commercial anti-DLAT antibodies are widely used for detecting DLAT in Western blot (WB), immunohistochemistry (IHC), and immunofluorescence (IF). Representative products include:
Autoimmune and Neurological Disorders
-
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP):
-
Anti-DLAT IgG/IgM antibodies are detected in 18% of CIDP patients, correlating with sensory ataxia (69% vs. 37% in seronegative cases), cranial nerve involvement (24%), and malignancy (20%) .
-
DLAT is highly expressed in dorsal root ganglion cells, suggesting a role in sensory neuropathy pathogenesis .
-
Cancer Prognosis
-
Gastric Cancer (GC): DLAT upregulation correlates with poor survival, lymph node metastasis, and Th2 immune cell infiltration. It is a potential cuproptosis-related prognostic marker .
Primary Biliary Cirrhosis (PBC):
-
DLAT is the primary antigen for antimitochondrial antibodies (AMA) in 95% of PBC cases, driving bile duct destruction .
Mechanistic Insights
-
Metabolic Regulation: DLAT supports ATP generation via acetyl-CoA production . Dysregulation is linked to diabetes and cancer .
-
Immune-Mediated Damage: Anti-DLAT antibodies may induce T-cell activation against sensory neurons or mitochondrial components .
Research Applications and Validation
-
Key Studies:
Limitations and Future Directions
Product Specs
Target Background
Q&A
Here’s a structured collection of FAQs tailored for academic researchers working with DLAT-1 antibodies, incorporating methodological insights and data from peer-reviewed studies:
How do I validate DLAT-1 antibody specificity in experimental models?
Methodological Answer:
-
Perform Western blot (WB) using cell lysates with known DLAT expression (e.g., HepG2, MCF-7) and include knockout controls .
-
Use immunoprecipitation (IP) followed by mass spectrometry to confirm target binding .
-
Validate cross-reactivity across species (human, mouse, rat) using tissues with confirmed DLAT expression (e.g., liver cancer vs. kidney tissue) .
-
Compare observed molecular weight (~69-70 kDa) against calculated weight (70 kDa) to rule out non-specific bands .
What are optimal dilution ranges for DLAT-1 antibodies in common applications?
Experimental Design Guidelines:
How does DLAT expression correlate with immune checkpoint markers in hepatocellular carcinoma (HCC)?
Data-Driven Analysis:
What functional pathways are enriched in DLAT-associated gene networks?
Multi-Omics Integration:
-
PPI Network: DLAT interacts with 259 genes (132 positive, 127 negative) .
-
Pathway Enrichment (KEGG):
Pathway Adjusted p-value Key Genes Metabolic reprogramming < 0.001 ACLY, IDH2 Immune regulation 0.003 CD274, CTLA4 -
Functional Validation: CRISPR/Cas9 knockout followed by RNA-seq to identify dysregulated metabolic and immune pathways.
How to resolve discrepancies in DLAT-1 antibody performance across studies?
Contradiction Analysis Framework:
Can DLAT-1 antibodies serve as biomarkers for non-oncological conditions?
Cross-Disciplinary Evidence:
-
CIDP Diagnosis: Anti-DLAT antibodies are detected in 12% of chronic inflammatory demyelinating polyneuropathy (CIDP) cases, correlating with sensory ataxia (OR = 3.2) .
-
Methodological Note: Screen patient sera via ELISA using recombinant DLAT protein, followed by confirmatory WB .
What are best practices for combining DLAT-1 IHC with PD-1/PD-L1 blockade studies?
Translational Workflow:
